Multiple Sclerosis

Global Advances In Health and Medicine

Volumn 2, Issue 1, 2013, Pages 50-56

  Gaby, Alan ^a  

^a NONE

Author keywords

Autoimmune disease; Fatty acids; Folic acid; Low fat diet; Multiple sclerosis; Vitamin B12; Vitamin B3; Vitamin D

Indexed keywords

ACETYLCARNITINE; ADENOSINE PHOSPHATE; AMANTADINE; BETA INTERFERON; CARNITINE; COD LIVER OIL; CYANOCOBALAMIN; CYCLOSPORIN; ESTRIOL; FISH OIL; FOLIC ACID; GLUCOCORTICOID; HERBACEOUS AGENT; INTERFERON; LINOLEIC ACID; MECOBALAMIN; NICOTINAMIDE; NYSTATIN; OLEIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; ORGANIC SOLVENT; PADMA 28; PLACEBO; PRASTERONE; THREONINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEGETABLE OIL; VITAMIN D;

ALLERGY; CANDIDIASIS; CLINICAL FEATURE; DIET SUPPLEMENTATION; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LIPID DIET; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPASTICITY; UNSPECIFIED SIDE EFFECT;

EID: 84901428863     PISSN: 2164957X     EISSN: 21649561     Source Type: Journal    
DOI: 10.7453/gahmj.2013.2.1.009     Document Type: Review

References (86)

1. Landtblom AM, Flodin U, Soderfeldt B, et al. Organic solvents and multiple sclerosis: a synthesis of the current evidence. Epidemiology. 1996;7:429-33.
2. Crinnion WJ. Results of a decade of naturopathic treatment for environmental illnesses: a review of clinical records. J Naturopathic Med. 1997;7(2):21-7.
3. Swank RL. Treatment of multiple sclerosis with low-fat diet: result of seven years of experience. Ann Intern Med. 1956;45:812-24.
4. Swank RL, Bourdillon RB. Multiple sclerosis: assessment of treatment with a modified low-fat diet. J Nerv Ment Dis. 1960;131:468-88.
5. Swank RL. Multiple sclerosis: twenty years on low fat diet. Arch Neurol. 1970;23:46074.
6. Swank RL, Grimsgaard A. Multiple sclerosis: the lipid relationship. Am J Clin Nutr. 1988;48:1387-93.
7. Swank RL. Multiple sclerosis: fat-oil relationship. Nutrition. 1991;7:368-76.
8. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet. 1990;336:37-9.
9. Swank RL, Goodwin J. Review of MS patient survival on a Swank low saturated fat diet. Nutrition. 2003;19:161-2.
10. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand. 2000;102:143-9.
11. Weinstock-Guttman B, Baier M, Park Y, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids. 2005;73:397-404.
12. Meyer MG, Johnston A, Coca AF. Is multiple sclerosis a manifestation of idioblaptic allergy? Psychiatr Q. 1954(Jan);28:57-71.
13. Jonez HD. The allergic aspects of multiple sclerosis. Calif Med. 1953;79:376-80.
14. Ehrentheil OF, Schulman MH, Alexander L. Role of food allergy in multiple sclerosis. Neurology. 1952;2:412-26.
15. Maas AG, Hogenhuis LAH. Multiple sclerosis and possible relationship to cocoa: a hypothesis. Ann Allergy. 1987;59:76-9.
16. Lange LS, Shiner M. Small-bowel abnormalities in multiple sclerosis. Lancet. 1976;2:1319-22.
17. Jellinek EH. Multiple sclerosis and diet. Lancet. 1974;2:1006-7.
18. Malosse D, Perron H, Sasco A, Seigneurin JM. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology. 1992;11:304-12.
19. Ag JBD. The distribution of multiple sclerosis in relation to the dairy industry and milk consumption. N Z Med J. 1976;83:427-30.
20. Agranoff BW, Goldberg D. Diet and the geographical distribution of multiple sclerosis. Lancet. 1974;2:1061-6.
21. Miller SL, Klurfeld DM, Loftus B, Kritchevsky D. Effect of essential fatty acid deficiency on myelin proteins. Lipids. 1984;19:478-80.
22. Wiggins RC. Myelin development and nutritional insufficiency. Brain Res Rev. 1982;4:151-75.
23. Clausen J, Moller J. Allergic encephalomyelitis induced by brain antigen after deficiency in polyunsaturated fatty acids during myelination. Acta Neurol Scand. 1967;43:375-88.
24. Selivonchick DP, Johnston PV. Fat deficiency in rats during development of the central nervous system and susceptibility to experimental allergic encephalomyelitis. J Nutr. 1975;105:288-300.
25. Levine S, Sowinski R. Effect of essential fatty acid deficiency on experimental allergic encephalomyelitis in rats. J Nutr. 1980;110:891-6.
26. Hughes D, Keith AB, Mertin J, Caspary EA. Linoleic acid therapy in severe experimental allergic encephalomyelitis in the guinea-pig: suppression by continuous treatment. Clin Exp Immunol. 1980;41:523-31.
27. Baker RWR, Thompson RHS, Zilkha KJ. Serum fatty acids in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1964;27:408-14.
28. Belin J, Pettet N, Smith AD, et al. Linoleate metabolism in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1971;34:25-9.
29. Tsang WM, Belin J, Monro JA, et al. Relationship between plasma and lymphocyte linoleate in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1976;39:767-71.
30. Navarro X, Segura R. Plasma lipids and their fatty acid composition in multiple sclerosis. Acta Neurol Scand. 1988;78:152-7.
31. Love WC, Cashell A, Reynolds M, Callaghan N. Linoleate and fatty-acid patterns of serum lipids in multiple sclerosis and other diseases. Br Med J. 1974;3:18-21.
32. Neu IS. Essential fatty acids in the serum and cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand. 1983;67:151-63.
33. Yoshida M, Takase S, Itahara K, Nakanishi T. Linoleate and fatty acid compositions in the serum lipids of Japanese patients with multiple sclerosis. Acta Neurol Scand. 1983;68:362-4.
34. Gupta JK, Ingegno AP, Cook AW, Pertschuk LP. Multiple sclerosis and malabsorption. Am J Gastroenterol. 1977;68:560-5.
35. Joyce G, Field EJ. Further observations with the erythrocyte-unsaturated fatty acid test. Eur Neurol. 1980;19:266-72.
36. Field EJ, Shenton BK. Inhibitory effect of unsaturated fatty acids on lymphocyte-antigen interaction with special reference to multiple sclerosis. Acta Neurol Scand. 1975;52:121-36.
37. Field EJ, Shenton BK, Joyce G. Specific laboratory test for diagnosis of multiple sclerosis. Br Med J. 1974;1:412-4.
38. Tamblyn CH, Swank RL, Seaman GVF, Zukoski CF IV. Red cell electrophoretic mobility test for early diagnosis of multiple sclerosis. Neurol Res. 1980;2:69-83.
39. Field EJ, Joyce G. Multiple sclerosis: effect of gamma linolenate administration upon membranes and the need for extended clinical trials of unsaturated fatty acids. Eur Neurol. 1983;22:78-83.
40. Field EJ, Joyce G. Effect of prolonged ingestion of gamma-linolenate by MS patients. Eur Neurol. 1978;17:67-76.
41. Millar JHD, Zilkha KJ, Langman MJS, et al. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J. 1973;1:765-8.
42. Bates D, Fawcett PRW, Shaw DA, Weightman D. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. Br Med J. 1978;2:1390-1.
43. Paty DW, Cousin HK, Read S, Adlakha K. Linoleic acid in multiple sclerosis: failure to show any therapeutic benefit. Acta Neurol Scand. 1978;58:53-8.
44. Bates D, Fawcett PRW, Shaw DA, Weightman D. Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis. Br Med J. 1977;2:932-3.
45. Dworkin RH, Bates D, Millar JHD, Paty DW. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology. 1984;34:1441-5.
46. Nightingale S, Woo E, Smith AD, et al. Red blood cell and adipose tissue fatty acids in mild inactive multiple sclerosis. Acta Neurol Scand. 1990;82:43-50.
47. Cendrowski W. Multiple sclerosis and MaxEPA. Br J Clin Pract. 1986;40:365-7.
48. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986;21:193-200.
49. Bates D, Cartlidge NEF, French JM, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52:18-22.
50. Reynolds EH, Linnell JC. Vitamin B12 deficiency, demyelination, and multiple sclerosis. Lancet. 1987;2:920.
51. Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. J Neuroimmunol. 1992;40:225-30.
52. Reynolds EH, Linnell JC, Faludy JE. Multiple sclerosis associated with vitamin B12 deficiency. Arch Neurol. 1991;48:808-11.
53. Kira J, Tobimatsu S, Goto I. Vitamin B12 metabolism and massive-dose methyl vitamin B12 therapy in Japanese patients with multiple sclerosis. Intern Med. 1994;33:82-6.
54. Anonymous. Vitamin B12 in multiple sclerosis. JAMA. 1950;143:1272.
55. Wade DT, Young CA, Chaudhuri KR, Davidson DLW. A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:246-9.
56. Booth CB, Lawyer T Jr, von Storch TJC. Vitamin B12 in the treatment of multiple sclerosis. JAMA. 1951;147:894.
57. Lebrun C, Alchaar H, Candito M, et al. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler. 2006;12:321-4.
58. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004;218:103-8.
59. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med. 1997;216:21-7.
60. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223:230-3.
61. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60-5.
62. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci. 1996;93:7861-4.
63. Nieves J, Cosman F, Herbert J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44:1687-92.
64. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86:645-51.
65. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74:1852-9.
66. Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:565-71.
67. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011;77:1611-8.
68. Kaneko S, Wang J, Kaneko M, et al. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci. 2006;26:9794-804.
69. Lee KC, Patterson V, Roberts G, Trimble E. The antispastic effect of L-threonine. In: Lubec and Rosenthal, editors. Amino acids: chemistry, biology and medicine. Berlin, Heidelberg: Springer; 1990:658-63.
70. Lee A, Patterson V. A double-blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand. 1993;88:334-8.
71. Hauser SL, Doolittle TH, Lopez-Bresnahan M, et al. An antispasticity effect of threonine in multiple sclerosis. Arch Neurol. 1992;49:923-6.
72. Isager H. Serum folate in patients with multiple sclerosis. Acta Neurol Scand. 1970;46:238-42.
73. Heathcote JG. Multiple sclerosis. Lancet. 1975;1:344.
74. Becker KW, Kienecker EW, Dick P, Bonke D. Enhancement of regeneration of the saphenous nerve after treatment with vitamins B1, B6, and B12 after cold lesion in the rabbit. Ann N Y Acad Sci. 1990;585:477-9.
75. Wiggins RC. Myelin development and nutritional insufficiency. Brain Res Rev. 1982;4:151-75.
76. Zimmerman AW, Matthieu JM, Quarles RH, et al. Hypomyelination in copper-deficient rats. Prenatal and postnatal copper replacement. Arch Neurol. 1976;33:111-9.
77. Truss CO. The role of Candida albicans in human illness. J Orthomolec Psychiatry. 1981;10:228-38.
78. Crook W. The yeast connection. Jackson, TN: Professional Books; 1986:211-9.
79. Zouali M, Drouhet E, Eyquem A. Evaluation of auto-antibodies in chronic mucocutaneous candidiasis without endocrinopathy. Mycopathologia. 1983;84:87-93.
80. Gay D, Dick G, Upton G. Multiple sclerosis associated with sinusitis: casecontrolled study in general practice. Lancet. 1986;1:815-9.
81. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002;52:421-8.
82. Kuempfel T, Then Bergh F, Friess E, et al. Neuroendocrine-immune system interactions: dehydroepiandrosterone plasma levels in multiple sclerosis. Ann Neurol. 1997;42:428.
83. Kumpfel T, Then Bergh F, Friess E, et al. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. Neuroendocrinology. 1999;70:431-8.
84. Tellez N, Comabella M, Julia E, et al. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler. 2006;12:487-94.
85. Korwin-Piotrowska T, Nocon D, Stankowska-Chomicz A, et al. Experience of Padma 28 in multiple sclerosis. Phytother Res. 1992;6:133-6.
86. Lowry ML, Moore RW, Cailliet R. Adenosine-5-monophosphate in the treatment of multiple sclerosis. Am J Med Sci. 1953;226:73-83.